A61K 40/44
Fungal antigens
A61K40/44 (Fungal antigens) appears on 36 US grants and 61 published applications in this corpus.
Search patents in A61K- Granted patents
- 36
- Published applications
- 61
- Assignees
- 44
- Inventors
- 76
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 4 |
| 2007 | 0 | 4 |
| 2008 | 0 | 0 |
| 2009 | 1 | 3 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 2 | 3 |
| 2013 | 2 | 4 |
| 2014 | 4 | 2 |
| 2015 | 2 | 2 |
| 2016 | 0 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 3 | 11 |
| 2020 | 3 | 1 |
| 2021 | 1 | 3 |
| 2022 | 3 | 6 |
| 2023 | 5 | 3 |
| 2024 | 3 | 5 |
| 2025 | 2 | 2 |
By publication year.
Recent patents
- Glucuronoxylomannan (GXM) receptor chimeric antigen receptors and use thereof2 Sep 2025US 12,404,347 B2Board of Regents, The University of Texas System
- Aspergillus antigen chimeric receptors and use thereof13 May 2025US 12,297,259 B2Board of Regents, The University of Texas System
- Tumoricidal and antimicrobial compositions and methods20 Aug 2024US 12,064,450 B2ImmunityBio, Inc.
- Tumoricidal and antimicrobial compositions and methods7 May 2024US 11,975,027 B2ImmunityBio, Inc.
- Adoptive T cell therapy 29 Apr 2024US 11,951,127 B2New South Wales Health Pathology
- Switchable car-t therapies for treating human cancers30 Oct 2025US 2025/0332258 A1The Scripps Research Institute
- Tumoricidal and antimicrobial compositions and methods29 May 2025US 2025/0170181 A1ImmunityBio, Inc.
- Tumoricidal and antimicrobial compositions and methods7 Nov 2024US 2024/0366674 A1ImmunityBio, Inc.
- Tumor lysate loaded particles24 Oct 2024US 2024/0350540 A1Orbis Health Solutions LLC
- Genetically engineered cell-derived vaccines24 Oct 2024US 2024/0350629 A1The Regents of the University of California
Most cited
By later US patents
- Yeast-dendritic cell vaccines and uses thereof61US 7,083,787 B2GlobeImmune, Inc. · 2006
- Yeast-antigen compositions methods of making the same43US 7,595,060 B2GlobeImmune, Inc. · 2009
- Therapeutic uses of allogeneic myeloid progenitor cells31US 7,811,815 B2The Board of Trustees of the Leland Stanford Junior University · 2010
- Therapeutic uses of allogeneic myeloid progenitor cells26US 9,545,427 B2The Board of Trustees of the Leland Stanford Junior University · 2017
- Therapeutic uses of allogeneic myeloid progenitor cells25US 8,980,329 B2The Board of Trustees of the Leland Stanford Junior University · 2015